Radiation dose and fractionation regimen for limited stage small cell lung cancer: a survey of current practice patterns of Chinese radiation oncologists
10.3760/cma.j.cn113030-20220207-00051
- VernacularTitle:局限期小细胞肺癌放射治疗决策的现况调查
- Author:
Chang XU
1
;
Meng LI
;
Ming CHEN
;
Shuchai ZHU
;
Nan BI
;
Xuwei CAI
;
Shuanghu YUAN
;
Jianzhong CAO
;
Xiao HU
;
Jiancheng LI
;
Wei ZHOU
;
Ping WANG
;
Jun WANG
;
Lujun ZHAO
;
Ningbo LIU
Author Information
1. 天津医科大学肿瘤医院放疗科，国家肿瘤临床医学研究中心天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津 300060
- Keywords:
Small cell lung carcinoma, limited stage;
Radiography, thoracic;
Hyper-fractionation;
Hypo-fractionation
- From:
Chinese Journal of Radiation Oncology
2023;32(2):93-98
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the radiation dose and fractionation regimens for limited stage small cell lung cancer (LS-SCLC) in Chinese radiation oncologists.Methods:Over 500 radiation oncologists were surveyed through questionnaire for radiation dose and fractionation regimens for LS-SCLC and 216 valid samples were collected for further analysis. All data were collected by online questionnaire designed by WJX software. Data collection and statistical analysis were performed by SPSS 25.0 statistical software. The differences in categorical variables among different groups were analyzed by Chi-square test and Fisher's exact test. Results:Among 216 participants, 94.9% preferred early concurrent chemoradiotherapy, 69.4% recommended conventional fractionation, 70.8% preferred a total dose of 60 Gy when delivering conventional radiotherapy and 78.7% recommended 45 Gy when administering hyperfractionated radiotherapy.Conclusions:Despite differences in LS-SCLC treatment plans, most of Chinese radiation oncologists prefer to choose 60 Gy conventional fractionated radiotherapy as the main treatment strategy for LS-SCLC patients. Chinese Society of Clinical Oncology (CSCO), National Comprehensive Cancer Network (NCCN) and Chinese Medical Association guidelines or expert consensus play a critical role in guiding treatment decision-making.
